Rallybio Corp (RLYB)

NASDAQHealth CareBiotechnologySnapshot 2026-09-04

$16.93+0.30%

Close 2026-09-04 · 1-day change

QuarterlyIQ Insights · RLYB

Financials

Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.

Income Statement

Period

View

Order

Figures in millions of USD, except per-share and ratios.

	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenues
Revenues	—	0.9	0.6	—	—	—	—
Total Revenues	—	0.9	0.6	—	—	—	—
Operating Expenses & Income
R&D Expenses	11.4	19.6	41.5	53.5	40.7	26.9	17.6
Operating Income	(27.7)	(33.1)	(60.5)	(78.9)	(67.9)	(45.6)	(25.3)
Earnings from Continuing Operations
Interest Expense	—	—	—	—	0.0	0.0	0.0
Other Non-Operating Income / Expenses	74.6	25.0	5.0	6.4	2.3	0.1	0.4
EBT, Incl. Unusual Items	46.9	(8.1)	(55.5)	(72.5)	(65.6)	(45.5)	(24.9)
Income Tax Expense	—	—	—	0.0	0.0	0.0	(0.0)
Net Income
Net Income	45.6	(9.0)	(57.8)	(74.6)	(66.7)	(47.0)	(26.4)
Per Share
Basic EPS	7.99	(1.59)	(1.33)	(1.84)	(2.09)	(1.84)	—
Diluted EPS	7.86	(1.59)	(1.33)	(1.84)	(2.09)	(1.84)	—
Basic Weighted Avg Shares	5.7	5.6	43.5	40.4	31.8	25.5	—
Diluted Weighted Avg Shares	5.8	5.6	43.5	40.4	31.8	25.5	—
Supplemental
EBITDA	—	(33.0)	(60.4)	(78.8)	(67.7)	(45.5)	(25.2)
EBIT	(27.7)	(33.1)	(60.5)	(78.9)	(67.9)	(45.6)	(25.3)
Effective Tax Rate	—	—	—	0.0%	0.0%	0.0%	0.1%

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.